SEC Comment Letter for ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Apr 27, 2020

ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: April 27, 2020 · CIK: 0001513525 · Accession: 0000000000-20-003603

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-237793

Date

April 27, 2020

Author

William B. Stilley, III

Form

UPLOAD

Company

ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)

Letter

United States securities and exchange commission logo April 27, 2020 William B. Stilley, III President and Chief Executive Officer Adial Pharmaceuticals, Inc. 1180 Seminole Trail, Suite 495 Charlottesville, VA 22901 Re:Adial Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 22, 2020 File No. 333-237793 Dear Mr. Stilley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at (202) 551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq.

Show Raw Text

United States securities and exchange commission logo
April 27, 2020
William B. Stilley, III
President and Chief Executive Officer
Adial Pharmaceuticals, Inc.
1180 Seminole Trail, Suite 495
Charlottesville, VA 22901
Re:Adial Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 22, 2020
File No. 333-237793
Dear Mr. Stilley:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Chris Edwards at (202) 551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Leslie Marlow, Esq.

SecProbe.io